Alto Neuroscience, Inc. (NYSE:ANRO - Get Free Report)'s share price hit a new 52-week high during mid-day trading on Tuesday . The company traded as high as $36.99 and last traded at $36.4220, with a volume of 867909 shares traded. The stock had previously closed at $34.28.
Analyst Upgrades and Downgrades
Several research firms recently issued reports on ANRO. Robert W. Baird cut their target price on Alto Neuroscience from $38.00 to $36.00 and set an "outperform" rating on the stock in a research note on Monday, May 18th. Bank of America began coverage on Alto Neuroscience in a report on Tuesday, May 5th. They issued a "buy" rating and a $35.00 price objective for the company. HC Wainwright lifted their price objective on Alto Neuroscience from $50.00 to $55.00 and gave the stock a "buy" rating in a research report on Monday, August 17th. Wedbush boosted their target price on Alto Neuroscience from $24.00 to $26.00 and gave the company a "neutral" rating in a research note on Thursday, August 13th. Finally, Zacks Research upgraded Alto Neuroscience from a "strong sell" rating to a "hold" rating in a report on Thursday, August 20th. Eight investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Alto Neuroscience has a consensus rating of "Moderate Buy" and a consensus price target of $37.25.
Read Our Latest Stock Analysis on ANRO
Alto Neuroscience Stock Performance
The company has a debt-to-equity ratio of 0.07, a quick ratio of 14.85 and a current ratio of 14.85. The stock has a market capitalization of $1.43 billion, a P/E ratio of -15.05 and a beta of 1.06. The business has a 50-day moving average price of $27.67 and a 200 day moving average price of $23.59.
Alto Neuroscience (NYSE:ANRO - Get Free Report) last posted its quarterly earnings results on Wednesday, August 12th. The company reported ($0.65) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.73) by $0.08. As a group, sell-side analysts forecast that Alto Neuroscience, Inc. will post -2.68 EPS for the current fiscal year.
Institutional Trading of Alto Neuroscience
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Commodore Capital LP grew its position in shares of Alto Neuroscience by 49.4% during the 1st quarter. Commodore Capital LP now owns 2,723,196 shares of the company's stock valued at $61,217,000 after acquiring an additional 900,000 shares during the period. Vestal Point Capital LP raised its holdings in Alto Neuroscience by 161.6% in the 4th quarter. Vestal Point Capital LP now owns 2,485,000 shares of the company's stock worth $44,233,000 after purchasing an additional 1,535,000 shares during the period. Perceptive Advisors LLC lifted its position in Alto Neuroscience by 12.6% during the first quarter. Perceptive Advisors LLC now owns 2,009,893 shares of the company's stock valued at $45,182,000 after purchasing an additional 225,500 shares in the last quarter. Armistice Capital LLC lifted its position in Alto Neuroscience by 0.7% during the third quarter. Armistice Capital LLC now owns 1,636,000 shares of the company's stock valued at $6,577,000 after purchasing an additional 12,000 shares in the last quarter. Finally, Spruce Street Capital LP lifted its position in Alto Neuroscience by 494.7% during the first quarter. Spruce Street Capital LP now owns 1,325,210 shares of the company's stock valued at $29,116,000 after purchasing an additional 1,102,366 shares in the last quarter.
Alto Neuroscience Company Profile
(
Get Free Report)
Alto Neuroscience NYSE: ANRO is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.
Alto's proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Alto Neuroscience, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alto Neuroscience wasn't on the list.
While Alto Neuroscience currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
